Pharmanet Development Group Hosts Phase IV Symposium in London on June 3, 2010
News May 13, 2010
PharmaNet Development Group, Inc., announce that it is hosting a complimentary symposium entitled "Safety and Value: Critical Success Factors for Post-Approval Research" at the Royal College of Surgeons in London, United Kingdom on June 3, 2010.
Post-approval studies are essential in characterizing the real-world performance of medical products in terms of safety, effectiveness, economic value and quality of life.
During this symposium, industry leaders will join PharmaNet experts to discuss techniques to optimize post-approval research including:
• Strategic Post-Approval Research Planning, Jeff Trotter, Executive Vice President, Phase IV Development, PharmaNet
• The Evolving Post-Approval Regulatory Environment in Europe, Franz Buchholzer, Vice President, Regulatory Operations, PharmaNet
• Issues in Safety, Epidemiology, and Risk Management, Rav Seeruthun, Head of CNS and GI, Eisai Europe and George Seaton, Clinical Trials Manager, Eisai Europe
• Obtaining Real-World Evidence through Observational Research and Patient Registries, Ron Weishaar, Executive Director, Observational Research, PharmaNet
• Establishing Product Value through Health Economics and Outcomes Research (HEOR), Michael Nelson, Executive Director, Health Economics and Outcomes Research, PharmaNet
• Post-Approval Case Studies, Ken Ashman, Executive Director, Phase IV European Operations, PharmaNet.
Lonza Expands Encapsulation and HPAPI Capabilities in North AmericaNews
Expanding our capabilities into commercial-scale encapsulation responds to our customers' desire to maintain programs at the Tampa, FL (USA) site from clinical development to commercialization.READ MORE
Researchers Discover Key Link Between Mitochondria and Cocaine AddictionNews
Researchers were able to block response in mitochondria to cocaine.READ MORE
Tuberculosis Vaccine Trial Results Offer Potential for BCG RevaccinationNews
The study is the first 'prevention of infection' trial conducted for tuberculosis, the world's leading infectious disease killer.READ MORE